4cbt
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ==Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for | + | ==Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease== |
<StructureSection load='4cbt' size='340' side='right' caption='[[4cbt]], [[Resolution|resolution]] 3.03Å' scene=''> | <StructureSection load='4cbt' size='340' side='right' caption='[[4cbt]], [[Resolution|resolution]] 3.03Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
Line 22: | Line 22: | ||
</div> | </div> | ||
<div class="pdbe-citations 4cbt" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4cbt" style="background-color:#fffaf0;"></div> | ||
- | |||
- | ==See Also== | ||
- | *[[Histone deacetylase|Histone deacetylase]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
Line 36: | Line 33: | ||
[[Category: Breccia, P]] | [[Category: Breccia, P]] | ||
[[Category: Burli, R W]] | [[Category: Burli, R W]] | ||
+ | [[Category: Connell, C O]] | ||
[[Category: Dominguez, C]] | [[Category: Dominguez, C]] | ||
[[Category: Haughan, A F]] | [[Category: Haughan, A F]] | ||
Line 52: | Line 50: | ||
[[Category: Mueller, I]] | [[Category: Mueller, I]] | ||
[[Category: Munoz-Sanjuan, I]] | [[Category: Munoz-Sanjuan, I]] | ||
- | [[Category: OConnell, C]] | ||
[[Category: Penrose, S D]] | [[Category: Penrose, S D]] | ||
[[Category: Richardson, C M]] | [[Category: Richardson, C M]] |
Revision as of 06:34, 7 February 2018
Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease
|
Categories: Histone deacetylase | Human | Aziz, O | Beaumont, V | Beconi, M | Breccia, P | Burli, R W | Connell, C O | Dominguez, C | Haughan, A F | Hughes, S | Jarvis, R | Lamers, M | Leonard, P | Luckhurst, C A | Lyons, K A | Maillard, M | Mangette, J | Matthews, K L | McAllister, G | McNeil, H | Mead, T | Mueller, I | Munoz-Sanjuan, I | Penrose, S D | Richardson, C M | Stones, L | Stott, A J | Vann, J | Wall, M | Wishart, G | Yates, D | Amyotrophic lateral sclerosis | Class iia histone deacetylase inhibitor | Cyclopropanation | Huntingtons disease | Hydrolase | Hydroxamic acid | Muscle atrophy | Neurodegeneration | Sar